Bor-wen Wu

Biography

 Bor-Wen Wu spent 13 years as a biochemist at Agouron Pharmaceuticals, Inc., Warner-Lambert, and Pfizer. He worked mainly on HIV-related projects and, as a member of a structure-based drug design team, made significant contribution to the development of Viracept, an HIV protease inhibitor that was approved in 1996. In 2002, he founded DesigneRx Pharmaceuticals, Inc., a pilot cGMP facility for biologics in California. In 2003, he founded TDW Pharmaceuticals, Inc.

Research Interest

 ophthamology